期刊
EXPERIMENTAL BRAIN RESEARCH
卷 234, 期 11, 页码 3225-3232出版社
SPRINGER
DOI: 10.1007/s00221-016-4720-7
关键词
Substantia nigra; Striatum; Parkinson's disease; Photobiomodulation; 670 nm
资金
- Michael J Fox Foundation
- Credit Agricole Sud Rhones Alpes
- Fondation Philanthropique Edmond J Safra
- France Parkinson
- French National Research Agency (ANR Carnot Institute)
- Tenix corp
- Salteri family and our industry partners
We have reported previously that intracranial application of near-infrared light (NIr) reduces clinical signs and offers neuroprotection in a subacute MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) monkey model of Parkinson's disease. In this study, we explored whether NIr reduces the gliosis in this animal model. Sections of midbrain (containing the substantia nigra pars compacta; SNc) and striatum were processed for glial fibrillary acidic protein (to label astrocytes; GFAP) and ionised calcium-binding adaptor molecule 1 (to label microglia; IBA1) immunohistochemistry. Cell counts were undertaken using stereology, and cell body sizes were measured using ImageJ. Our results showed that NIr treatment reduced dramatically (similar to 75 %) MPTP-induced astrogliosis in both the SNc and striatum. Among microglia, however, NIr had a more limited impact in both nuclei; although there was a reduction in overall cell size, there were no changes in the number of microglia in the MPTP-treated monkeys after NIr treatment. In summary, we showed that NIr treatment influenced the glial response, particularly that of the astrocytes, in our monkey MPTP model of Parkinson's disease. Our findings raise the possibility of glial cells as a future therapeutic target using NIr.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据